1,000+ Opportunities

Find the right grant

Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.

This opportunity has expired. The information below is preserved for reference.Find similar active grants →

ClosedNational Institutes of Health · 2025

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

Quick Facts

Agency: National Institutes of Health
Funding: Up to $1.8M per award
Deadline: September 5, 2025 (Passed)
Status: Closed
Eligibility: Eligible applicants: Small businesses. Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

About This Grant

This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Technology Transfer Research (STTR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services with the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

Funding Opportunity Number: PAS-22-197. Assistance Listing: 93.853,93.866. Funding Instrument: G. Category: HL. Award Amount: Up to $1.8M per award.

View Original RFP

Get a weekly digest of new grants like this

A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.

Or search similar grants →

Eligibility Requirements

Eligible applicants: Small businesses.
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Frequently Asked Questions

Who can apply for Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)?

According to the current listing, eligibility includes: Eligible applicants: Small businesses. Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. Confirm the full requirements in the official notice before applying.

How much funding does Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) offer?

The current listing shows up to $1.8M per award. Verify award ceilings, matching requirements, and allowable costs in the official notice.

When is the deadline for Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)?

The published deadline was September 5, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.

Is Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) a federal grant?

Yes — Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.

How do I apply for Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)?

Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.

Competitive Intelligence

Past winners and funding trends for this program

Full analysis

Funder Profile

Ready to start your proposal?

Granted drafts, reviews, and strengthens your grant application — saving weeks of work. Professional members win a grant in 12 months or get a full refund.

Browse More Grants

Backed by the Granted Guarantee

Similar Grants from Other Funders

Dept. of the Army -- USAMRAA

Grants.govDeadline PassedBetween cycles — Between funding cycles - the FY26 required pre-application (LO…

DoW Duchenne Muscular Dystrophy, Idea Development Award

Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.

Up to $500,000 total costs per award (2-year maximum)Deadline: Sep 4, 2026 (passed)

National Institutes of Health Grant Writing Tips

NIH's New F99/K00 Parent Award Pays for Five Years and Requires You to Leave Your University to Collect the Last Three

PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.

Read article

The White House Drafted a Veto Committee for NIH Grants. It Died in Four Days — and Section 157 Is Why.

A draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.

Read article

NIH Just Collapsed Its Entire R25 Landscape Into Three Parent NOFOs — and the First Deadline Is September 25

PA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.

Read article